Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 373 to 377 of 377 entries
Sorted by: Best Match Show Resources per page
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

Nature

Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M.
PMID: 33762733
Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24.

Hepatocellular carcinoma (HCC) can have viral or non-viral causes

Cite
Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450-456doi: 10.1038/s41586-021-03362-0.
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., Müller, F., Sinha, A., Friebel, E., Engleitner, T., Lenggenhager, D., Moncsek, A., Heide, D., Stirm, K., Kosla, J., Kotsiliti, E., Leone, V., Dudek, M., Yousuf, S., Inverso, D., Singh, I., Teijeiro, A., Castet, F., Montironi, C., Haber, P. K., Tiniakos, D., Bedossa, P., Cockell, S., Younes, R., Vacca, M., Marra, F., Schattenberg, J. M., Allison, M., Bugianesi, E., Ratziu, V., Pressiani, T., D'Alessio, A., Personeni, N., Rimassa, L., Daly, A. K., Scheiner, B., Pomej, K., Kirstein, M. M., Vogel, A., Peck-Radosavljevic, M., Hucke, F., Finkelmeier, F., Waidmann, O., Trojan, J., Schulze, K., Wege, H., Koch, S., Weinmann, A., Bueter, M., Rössler, F., Siebenhüner, A., De Dosso, S., Mallm, J. P., Umansky, V., Jugold, M., Luedde, T., Schietinger, A., Schirmacher, P., Emu, B., Augustin, H. G., Billeter, A., Müller-Stich, B., Kikuchi, H., Duda, D. G., Kütting, F., Waldschmidt, D. T., Ebert, M. P., Rahbari, N., Mei, H. E., Schulz, A. R., Ringelhan, M., Malek, N., Spahn, S., Bitzer, M., Ruiz de Galarreta, M., Lujambio, A., Dufour, J. F., Marron, T. U., Kaseb, A., Kudo, M., Huang, Y. H., Djouder, N., Wolter, K., Zender, L., Marche, P. N., Decaens, T., Pinato, D. J., Rad, R., Mertens, J. C., Weber, A., Unger, K., Meissner, F., Roth, S., Jilkova, Z. M., Claassen, M., Anstee, Q. M., Amit, I., Knolle, P., Becher, B., Llovet, J. M., & Heikenwalder, M. (2021). NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 592(7854), 450-456. https://doi.org/10.1038/s41586-021-03362-0
Pfister, Dominik, et al. "NASH limits anti-tumour surveillance in immunotherapy-treated HCC." Nature vol. 592,7854 (2021): 450-456. doi: https://doi.org/10.1038/s41586-021-03362-0
Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24. PMID: 33762733; PMCID: PMC8046670.
Copy Download .nbib Format: NLM
Vaginal Fractional Carbon Dioxide Laser Treatment and Changes in Vaginal Biomechanical Parameters.

Lasers in surgery and medicine

Lauterbach R, Gutzeit O, Matanes E, Linder R, Mick I, Aharoni S, Gruenwald I, Wiener Z, Lowenstein L.
PMID: 33834503
Lasers Surg Med. 2021 Nov;53(9):1146-1151. doi: 10.1002/lsm.23405. Epub 2021 Apr 09.

BACKGROUND AND OBJECTIVES: Vaginal fractional carbon dioxide (COSTUDY DESIGN/MATERIALS AND METHODS: We conducted a prospective cohort between June 2018 and January 2020. Inclusion criteria were vaginal looseness, decreased local sensation during sexual intercourse, and sexual dysfunction. All the participants...

Cite
Lauterbach R, Gutzeit O, Matanes E, et al. Vaginal Fractional Carbon Dioxide Laser Treatment and Changes in Vaginal Biomechanical Parameters. Lasers Surg Med. 2021;53(9):1146-1151doi: 10.1002/lsm.23405.
Lauterbach, R., Gutzeit, O., Matanes, E., Linder, R., Mick, I., Aharoni, S., Gruenwald, I., Wiener, Z., & Lowenstein, L. (2021). Vaginal Fractional Carbon Dioxide Laser Treatment and Changes in Vaginal Biomechanical Parameters. Lasers in surgery and medicine, 53(9), 1146-1151. https://doi.org/10.1002/lsm.23405
Lauterbach, Roy, et al. "Vaginal Fractional Carbon Dioxide Laser Treatment and Changes in Vaginal Biomechanical Parameters." Lasers in surgery and medicine vol. 53,9 (2021): 1146-1151. doi: https://doi.org/10.1002/lsm.23405
Lauterbach R, Gutzeit O, Matanes E, Linder R, Mick I, Aharoni S, Gruenwald I, Wiener Z, Lowenstein L. Vaginal Fractional Carbon Dioxide Laser Treatment and Changes in Vaginal Biomechanical Parameters. Lasers Surg Med. 2021 Nov;53(9):1146-1151. doi: 10.1002/lsm.23405. Epub 2021 Apr 09. PMID: 33834503.
Copy Download .nbib Format: NLM
Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility.

International journal of pharmaceutics

Noske S, Karimov M, Hansen M, Zatula N, Ewe A, Aigner A.
PMID: 34896217
Int J Pharm. 2021 Dec 08;612:121359. doi: 10.1016/j.ijpharm.2021.121359. Epub 2021 Dec 08.

Mesenchymal stromal cells (MSCs) are multipotent cells derived from different sources and able to differentiate into distinct cell lineages. For their possible biomedical application, the "tuning" of MSCs also involves the specific knockdown of defined target genes. A major...

Cite
Noske S, Karimov M, Hansen M, et al. Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility. Int J Pharm. 2021;612:121359doi: 10.1016/j.ijpharm.2021.121359.
Noske, S., Karimov, M., Hansen, M., Zatula, N., Ewe, A., & Aigner, A. (2021). Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility. International journal of pharmaceutics, 612121359. https://doi.org/10.1016/j.ijpharm.2021.121359
Noske, Sandra, et al. "Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility." International journal of pharmaceutics vol. 612 (2021): 121359. doi: https://doi.org/10.1016/j.ijpharm.2021.121359
Noske S, Karimov M, Hansen M, Zatula N, Ewe A, Aigner A. Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility. Int J Pharm. 2021 Dec 08;612:121359. doi: 10.1016/j.ijpharm.2021.121359. Epub 2021 Dec 08. PMID: 34896217.
Copy Download .nbib Format: NLM
Care Provider Behaviors That Shape Parent Identity as a "Good Parent" to Their Seriously Ill Child.

Palliative medicine reports

Neumann ML, Weaver MS, Lord B, Wiener L, Hinds PS.
PMID: 33937910
Palliat Med Rep. 2021 Apr 27;2(1):113-121. doi: 10.1089/pmr.2021.0005. eCollection 2021.

No abstract available.

Cite
Neumann ML, Weaver MS, Lord B, et al. Care Provider Behaviors That Shape Parent Identity as a "Good Parent" to Their Seriously Ill Child. Palliat Med Rep. 2021;2(1):113-121doi: 10.1089/pmr.2021.0005.
Neumann, M. L., Weaver, M. S., Lord, B., Wiener, L., & Hinds, P. S. (2021). Care Provider Behaviors That Shape Parent Identity as a "Good Parent" to Their Seriously Ill Child. Palliative medicine reports, 2(1), 113-121. https://doi.org/10.1089/pmr.2021.0005
Neumann, Marie L, et al. "Care Provider Behaviors That Shape Parent Identity as a "Good Parent" to Their Seriously Ill Child." Palliative medicine reports vol. 2,1 (2021): 113-121. doi: https://doi.org/10.1089/pmr.2021.0005
Neumann ML, Weaver MS, Lord B, Wiener L, Hinds PS. Care Provider Behaviors That Shape Parent Identity as a "Good Parent" to Their Seriously Ill Child. Palliat Med Rep. 2021 Apr 27;2(1):113-121. doi: 10.1089/pmr.2021.0005. eCollection 2021. PMID: 33937910; PMCID: PMC8086518.
Copy Download .nbib Format: NLM
Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility.

International journal of pharmaceutics

Noske S, Karimov M, Hansen M, Zatula N, Ewe A, Aigner A.
PMID: 34896217
Int J Pharm. 2021 Dec 08;612:121359. doi: 10.1016/j.ijpharm.2021.121359. Epub 2021 Dec 08.

Mesenchymal stromal cells (MSCs) are multipotent cells derived from different sources and able to differentiate into distinct cell lineages. For their possible biomedical application, the "tuning" of MSCs also involves the specific knockdown of defined target genes. A major...

Cite
Noske S, Karimov M, Hansen M, et al. Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility. Int J Pharm. 2021;612:121359doi: 10.1016/j.ijpharm.2021.121359.
Noske, S., Karimov, M., Hansen, M., Zatula, N., Ewe, A., & Aigner, A. (2021). Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility. International journal of pharmaceutics, 612121359. https://doi.org/10.1016/j.ijpharm.2021.121359
Noske, Sandra, et al. "Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility." International journal of pharmaceutics vol. 612 (2021): 121359. doi: https://doi.org/10.1016/j.ijpharm.2021.121359
Noske S, Karimov M, Hansen M, Zatula N, Ewe A, Aigner A. Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility. Int J Pharm. 2021 Dec 08;612:121359. doi: 10.1016/j.ijpharm.2021.121359. Epub 2021 Dec 08. PMID: 34896217.
Copy Download .nbib Format: NLM
Showing 373 to 377 of 377 entries